Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Debt-to-Equity : 0.01 (As of Dec. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Debt-to-Equity?

Eucrates Biomedical Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.06 Mil. Eucrates Biomedical Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Eucrates Biomedical Acquisition's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $8.54 Mil. Eucrates Biomedical Acquisition's debt to equity for the quarter that ended in Dec. 2022 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eucrates Biomedical Acquisition's Debt-to-Equity or its related term are showing as below:

EUCRU' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.01
Current: 0.01

During the past 3 years, the highest Debt-to-Equity Ratio of Eucrates Biomedical Acquisition was 0.01. The lowest was 0.01. And the median was 0.01.

EUCRU's Debt-to-Equity is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.125 vs EUCRU: 0.01

Eucrates Biomedical Acquisition Debt-to-Equity Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Debt-to-Equity Chart

Eucrates Biomedical Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-Equity

0.01

Eucrates Biomedical Acquisition Quarterly Data
	Aug20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Equity	Get a 7-Day Free Trial					-	-	-	-	0.01

Competitive Comparison of Eucrates Biomedical Acquisition's Debt-to-Equity

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eucrates Biomedical Acquisition's Debt-to-Equity Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Debt-to-Equity falls into.

Eucrates Biomedical Acquisition Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eucrates Biomedical Acquisition's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.06	+	0)	/	8.536
	=	0.01

Eucrates Biomedical Acquisition's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.06	+	0)	/	8.536
	=	0.01

Eucrates Biomedical Acquisition (NAS:EUCRU) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eucrates Biomedical Acquisition Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

250 West 55th Street, Suite 13D, New York, NY, USA, 10019

Website

Eucrates Biomedical Acquisition Corp is a blank check company.

Executives

Stelios Papadopoulos	director, 10 percent owner	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell	director	270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro	director	2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena	director, 10 percent owner, officer: Chief Executive Officer	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal	officer: Vice President	250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova	officer: Chief Financial Officer	250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe	officer: Senior Vice President	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis	director, officer: President, COO	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal	director	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023